Acorda Therapeutics Inc EBITDA margin
Was ist das EBITDA margin von Acorda Therapeutics Inc?
EBITDA margin von Acorda Therapeutics Inc ist -3.45%
Was ist die Definition von EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Acorda Therapeutics Inc
Was macht Acorda Therapeutics Inc?
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Unternehmen mit ebitda margin ähnlich Acorda Therapeutics Inc
- Gold By Gold SA hat EBITDA margin von -3.47%
- Dominate hat EBITDA margin von -3.47%
- China Natural Resources Inc hat EBITDA margin von -3.46%
- Fe hat EBITDA margin von -3.46%
- I.T hat EBITDA margin von -3.46%
- Hermitage Offshore Services hat EBITDA margin von -3.46%
- Acorda Therapeutics Inc hat EBITDA margin von -3.45%
- Zinc Media plc hat EBITDA margin von -3.43%
- China Shun Ke Long hat EBITDA margin von -3.43%
- Umang Dairies hat EBITDA margin von -3.42%
- China Jo-Jo Drugstores Inc hat EBITDA margin von -3.42%
- GE T&D India hat EBITDA margin von -3.40%
- Kirkland`s Inc hat EBITDA margin von -3.40%